← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

RAPT Therapeutics, Inc. (RAPT) 10-Year Financial Performance & Capital Metrics

RAPT •
HealthcareBiotechnologyImmunology and Inflammation Therapies
AboutRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Show more
  • Revenue $0
  • EBITDA -$135M -7.2%
  • Net Income -$130M -11.2%
  • EPS (Diluted) -25.49 -4.6%
  • Gross Margin -
  • EBITDA Margin -
  • Operating Margin -
  • Net Margin -
  • ROE -77.09% -29.4%
  • ROIC -155.69% -162.8%
  • Debt/Equity 0.02 -49.6%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Momentum leader: RS Rating 98 (top 2%)
  • ✓Trading near 52-week high

✗Weaknesses

  • ✗Weak Piotroski F-Score: 2/9
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y-
TTM-

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM1.73%

EPS CAGR

10Y-
5Y-
3Y-
TTM50.24%

ROCE

10Y Avg-59.56%
5Y Avg-57.23%
3Y Avg-60.38%
Latest-79.25%

Peer Comparison

Immunology and Inflammation Therapies
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
TGTXTG Therapeutics, Inc.4.75B30.09200.6040.8%13.31%21.87%1.14
APLSApellis Pharmaceuticals, Inc.2.65B20.96116.44-11.77%3.25%7.48%1.71%0.30
ARGXargenx SE47.46B766.9260.0178.6%23.34%15.14%0.01
KNSAKiniksa Pharmaceuticals, Ltd.3.39B44.4959.3260.09%17.52%20.92%0.75%0.02
AUPHAurinia Pharmaceuticals Inc.1.88B14.176.8520.38%101.47%49.4%7.22%0.13
GLPGGalapagos N.V.2.22B33.665.88303.48%28.85%9.92%0.00
AKTXAkari Therapeutics, Plc12.56B0.24-0.00-69.35%0.15
RAPTRAPT Therapeutics, Inc.7.65B57.98-2.27-69.51%0.02

Compare RAPT vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs ARGX

Compare head-to-head with argenx SE

vs CANF

Compare head-to-head with Can-Fite BioPharma Ltd.

Compare Top 5

vs ARGX, CANF, AKTX, ABVX

Profit & Loss

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+0005.04M3.81M1.53M00
Revenue Growth %-----24.38%-59.95%-100%-
Cost of Goods Sold+1.38M1.24M1.33M00000
COGS % of Revenue--------
Gross Profit+-1.38M-1.24M-1.33M5.04M3.81M1.53M00
Gross Margin %---100%100%100%--
Gross Profit Growth %-10.62%-7.52%479.1%-24.38%-59.95%-100%-
Operating Expenses+29.33M36.95M43.63M58.26M73.02M87.32M127.06M136.1M
OpEx % of Revenue---1155.41%1915.08%5718.53%--
Selling, General & Admin3.71M5.18M8.72M12.77M16.04M20.24M26.06M28.88M
SG&A % of Revenue---253.29%420.59%1325.47%--
Research & Development25.62M31.77M34.91M45.48M56.98M67.08M101M107.22M
R&D % of Revenue---902.12%1494.49%4393.06%--
Other Operating Expenses216K800K1.29M00000
Operating Income+-29.33M-36.95M-43.63M-53.21M-69.21M-85.8M-127.06M-136.1M
Operating Margin %----1055.41%-1815.08%-5618.53%--
Operating Income Growth %--25.97%-18.09%-21.97%-30.06%-23.97%-48.1%-7.11%
EBITDA+-27.95M-35.71M-42.3M-52.09M-68.21M-84.75M-125.85M-134.9M
EBITDA Margin %----1033.14%-1788.96%-5549.97%--
EBITDA Growth %--27.78%-18.45%-23.15%-30.95%-24.24%-48.49%-7.19%
D&A (Non-Cash Add-back)1.38M1.24M1.33M1.12M996K1.05M1.22M1.2M
EBIT-29.33M-36.95M-43.63M-53.21M-69.21M-85.8M-127.06M-136.1M
Net Interest Income+00000000
Interest Income00000000
Interest Expense00000000
Other Income/Expense216K800K1.29M1.31M5K1.96M10.26M6.24M
Pretax Income+-29.11M-36.15M-42.34M-51.9M-69.2M-83.84M-116.8M-129.87M
Pretax Margin %----1029.39%-1814.95%-5490.37%--
Income Tax+00660K990K0000
Effective Tax Rate %100%100%101.56%101.91%100%100%100%100%
Net Income+-29.11M-36.15M-43M-52.89M-69.2M-83.84M-116.8M-129.87M
Net Margin %----1049.03%-1814.95%-5490.37%--
Net Income Growth %--24.15%-18.95%-23.01%-30.84%-21.15%-39.31%-11.19%
Net Income (Continuing)-29.11M-36.15M-43M-52.89M-69.2M-83.84M-116.8M-129.87M
Discontinued Operations00000000
Minority Interest00000000
EPS (Diluted)+-10.95-13.59-15.75-17.53-20.21-20.61-24.37-25.49
EPS Growth %--24.15%-15.94%-11.28%-15.29%-1.97%-18.25%-4.58%
EPS (Basic)-10.95-13.59-15.75-17.53-20.21-20.61-24.37-25.49
Diluted Shares Outstanding2.66M2.66M2.73M3.02M3.42M4.07M4.79M5.1M
Basic Shares Outstanding2.66M2.66M2.73M3.02M3.42M4.07M4.79M5.1M
Dividend Payout Ratio--------

Balance Sheet

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+48.24M65.06M80.51M115.6M192.97M252.69M161.78M235.24M
Cash & Short-Term Investments47.52M63.8M77.38M111.51M189.65M249.07M158.86M231.06M
Cash Only47.52M63.8M77.38M24.92M24.03M38.95M47.48M169.74M
Short-Term Investments00086.59M165.63M210.12M111.38M61.32M
Accounts Receivable00000000
Days Sales Outstanding--------
Inventory00000000
Days Inventory Outstanding--------
Other Current Assets0004.09M3.32M3.63M2.92M4.18M
Total Non-Current Assets+2.15M4.55M4.1M3.37M5.66M13.52M11.55M5.09M
Property, Plant & Equipment1.91M4.16M3.71M2.98M2.74M9.48M7.68M4.7M
Fixed Asset Turnover---1.69x1.39x0.16x--
Goodwill00000000
Intangible Assets00000000
Long-Term Investments605K598K000000
Other Non-Current Assets-369K-209K389K389K2.92M4.04M3.87M389K
Total Assets+50.39M69.61M84.6M118.97M198.64M266.21M173.33M240.32M
Asset Turnover---0.04x0.02x0.01x--
Asset Growth %-38.14%21.54%40.62%66.96%34.02%-34.89%38.65%
Total Current Liabilities+3.25M4.64M9.26M11.74M9.6M14.22M21.84M48.35M
Accounts Payable1.11M1.77M1.14M2.38M2M3.37M5.18M1.27M
Days Payables Outstanding291.68522.57313.68-----
Short-Term Debt00000000
Deferred Revenue (Current)004M4.1M1.02M000
Other Current Liabilities650K586K2.25M2.3M2.93M4.65M7.91M6.78M
Current Ratio14.85x14.01x8.70x9.84x20.11x17.77x7.41x4.87x
Quick Ratio14.85x14.01x8.70x9.84x20.11x17.77x7.41x4.87x
Cash Conversion Cycle--------
Total Non-Current Liabilities+109.55M969K2.23M3.05M2.66M6.82M4.46M2.07M
Long-Term Debt108.64M0000000
Capital Lease Obligations000006.82M4.46M2.07M
Deferred Tax Liabilities-108.64M-162.08M000000
Other Non-Current Liabilities905K969K2.23M2.19M2.15M000
Total Liabilities112.8M5.61M11.48M14.79M12.26M21.04M26.29M50.42M
Total Debt+108.64M161.11M0008.99M6.91M4.49M
Net Debt61.13M97.31M-77.38M-24.92M-24.03M-29.96M-40.57M-165.24M
Debt / Equity-2.52x---0.04x0.05x0.02x
Debt / EBITDA--------
Net Debt / EBITDA--------
Interest Coverage--------
Total Equity+-62.41M64M73.12M104.18M186.38M245.17M147.03M189.9M
Equity Growth %-202.55%14.26%42.47%78.9%31.54%-40.03%29.16%
Book Value per Share-23.4624.0626.7934.5354.4460.2730.6837.27
Total Shareholders' Equity-62.41M64M73.12M104.18M186.38M245.17M147.03M189.9M
Common Stock1K2K2K2K3K3K3K13K
Retained Earnings-82.81M-118.95M-161.95M-214.84M-284.05M-367.88M-484.68M-614.55M
Treasury Stock00000000
Accumulated OCI-3.77M-4K20K-177K-206K-26K103K50K
Minority Interest00000000

Cash Flow

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-27.12M-32.95M-35.47M-40.49M-61.03M-70.77M-97.05M-83.3M
Operating CF Margin %----803.07%-1600.47%-4634.64%--
Operating CF Growth %--21.49%-7.65%-14.14%-50.71%-15.97%-37.13%14.17%
Net Income-29.11M-36.15M-43M-52.89M-69.2M-83.84M-116.8M-129.87M
Depreciation & Amortization1.38M1.24M1.33M1.12M996K1.05M3.55M1.2M
Stock-Based Compensation716K1.17M2.05M8.69M9.95M11.26M019.93M
Deferred Taxes15K17K000000
Other Non-Cash Items-9K-14K9K248K1.53M2.09M10.7M-477K
Working Capital Changes-114K784K4.13M2.34M-4.3M-1.33M5.5M25.91M
Change in Receivables00000000
Change in Inventory00000000
Change in Payables-80K1.48M736K2.39M933K3.71M7.33M-8.46M
Cash from Investing+-1.12M-3.5M-843K-87.44M-81.35M-45.49M104.13M52.7M
Capital Expenditures-1.12M-3.5M-888K-398K-755K-845K-1.13M-122K
CapEx % of Revenue---7.89%19.8%55.34%--
Acquisitions00087.04M80.59M44.65M00
Investments--------
Other Investing0045K-87.04M-80.59M-44.65M00
Cash from Financing+30.1M52.73M49.9M75.46M141.48M131.18M1.45M152.85M
Debt Issued (Net)00000000
Equity Issued (Net)001000K1000K1000K1000K1000K1000K
Dividends Paid00000000
Share Repurchases00000000
Other Financing30.1M52.73M01.85M2.02M1.39M0845K
Net Change in Cash1.85M16.28M13.59M-52.47M-891K14.92M8.53M122.26M
Free Cash Flow+-28.25M-36.45M-36.36M-40.89M-61.78M-71.62M-98.17M-83.42M
FCF Margin %----810.97%-1620.27%-4689.98%--
FCF Growth %--29.05%0.25%-12.45%-51.09%-15.92%-37.08%15.03%
FCF per Share-10.62-13.70-13.32-13.55-18.04-17.61-20.49-16.37
FCF Conversion (FCF/Net Income)0.93x0.91x0.83x0.77x0.88x0.84x0.83x0.64x
Interest Paid00000000
Taxes Paid00660K990K0000

Key Ratios

Metric20172018201920202021202220232024
Return on Equity (ROE)--4538.23%-62.71%-59.66%-47.64%-38.85%-59.56%-77.09%
Return on Invested Capital (ROIC)--34.63%-41.67%-106.43%-42.97%-34.09%-59.25%-155.69%
Gross Margin---100%100%100%--
Net Margin----1049.03%-1814.95%-5490.37%--
Debt / Equity-2.52x---0.04x0.05x0.02x
FCF Conversion0.93x0.91x0.83x0.77x0.88x0.84x0.83x0.64x
Revenue Growth-----24.38%-59.95%-100%-

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.